Found: 54
Select item for more details and to access through your institution.
Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 10, p. 1412, doi. 10.1111/head.14631
- By:
- Publication type:
- Article
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 4, p. 628, doi. 10.1111/head.14103
- By:
- Publication type:
- Article
The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 8, p. 1683, doi. 10.1111/head.13914
- By:
- Publication type:
- Article
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 7, p. 1259, doi. 10.1111/head.13849
- By:
- Publication type:
- Article
FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 10, p. 1700, doi. 10.1111/head.13653
- By:
- Publication type:
- Article
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 10, p. 1762, doi. 10.1111/head.13642
- By:
- Publication type:
- Article
Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 8, p. 1286, doi. 10.1111/head.13613
- By:
- Publication type:
- Article
Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 1, p. 32, doi. 10.1111/head.13435
- By:
- Publication type:
- Article
Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2018, v. 58, n. 7, p. 933, doi. 10.1111/head.13342
- By:
- Publication type:
- Article
Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2018, v. 58, n. 4, p. 512, doi. 10.1111/head.13254
- By:
- Publication type:
- Article
Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale.
- Published in:
- Headache: The Journal of Head & Face Pain, 2017, v. 57, n. 4, p. 570, doi. 10.1111/head.13028
- By:
- Publication type:
- Article
A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
- Published in:
- Headache: The Journal of Head & Face Pain, 2016, v. 56, n. 8, p. 1280, doi. 10.1111/head.12878
- By:
- Publication type:
- Article
Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2016, v. 56, n. 5, p. 821, doi. 10.1111/head.12774
- By:
- Publication type:
- Article
Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention ( AMPP) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2015, v. 55, n. 6, p. 825, doi. 10.1111/head.12556
- By:
- Publication type:
- Article
Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention ( AMPP) Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2015, v. 55, n. 4, p. 502, doi. 10.1111/head.12553
- By:
- Publication type:
- Article
OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
- Published in:
- Journal of Headache & Pain, 2018, v. 19, n. 1, p. 0, doi. 10.1186/s10194-018-0840-8
- By:
- Publication type:
- Article
The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
- Published in:
- Journal of Headache & Pain, 2017, v. 18, n. 1, p. 1, doi. 10.1186/s10194-017-0784-4
- By:
- Publication type:
- Article
Long-term safety and efficacy of onabotulinumtoxinA for the prevention of chronic migraine in a South Korean population: COMPEL study.
- Published in:
- Neurology Asia, 2019, v. 24, n. 2, p. 127
- By:
- Publication type:
- Article
Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 1, p. 692, doi. 10.1007/s12325-021-01923-3
- By:
- Publication type:
- Article
Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
- Published in:
- Pain Practice, 2016, v. 16, n. 8, p. 1073, doi. 10.1111/papr.12408
- By:
- Publication type:
- Article
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
- Published in:
- Journal of Primary Care & Community Health, 2020, p. 1, doi. 10.1177/2150132720959936
- By:
- Publication type:
- Article
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
- Published in:
- Journal of Primary Care & Community Health, 2020, p. 1, doi. 10.1177/2150132720959936
- By:
- Publication type:
- Article
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
- Published in:
- Journal of Neurology, 2014, v. 261, n. 7, p. 1309, doi. 10.1007/s00415-014-7343-6
- By:
- Publication type:
- Article
Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
- Published in:
- Journal of Headache & Pain, 2019, v. 20, n. 1, p. 1, doi. 10.1186/s10194-018-0952-1
- By:
- Publication type:
- Article
Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
- Published in:
- Journal of Headache & Pain, 2019, v. 20, n. 1, p. 1, doi. 10.1186/s10194-018-0953-0
- By:
- Publication type:
- Article
Long‐Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2021, v. 13, n. 10, p. 1079, doi. 10.1002/pmrj.12517
- By:
- Publication type:
- Article
Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study.
- Published in:
- Journal of Headache & Pain, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s10194-024-01834-y
- By:
- Publication type:
- Article
Poster 114: Efficacy and Safety of OnabotulinumtoxinA in an Open‐Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, n. 91, p. S171, doi. 10.1016/j.pmrj.2017.08.061
- By:
- Publication type:
- Article
Poster 79: The Adult Spasticity International Registry (ASPIRE) Study: 1‐Year Results.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, n. 91, p. S162, doi. 10.1016/j.pmrj.2017.08.035
- By:
- Publication type:
- Article
Poster 66: The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, n. 91, p. S158, doi. 10.1016/j.pmrj.2017.08.023
- By:
- Publication type:
- Article
Poster 79: The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, p. S162, doi. 10.1016/j.pmrj.2017.08.035
- By:
- Publication type:
- Article
Poster 114: Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, p. S171, doi. 10.1016/j.pmrj.2017.08.061
- By:
- Publication type:
- Article
Poster 66: The Adult Spasticity International Registry (ASPIRE) Study: Treatment Utilization Patterns in Patients Treated for Both Upper and Lower Limb Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2017, v. 9, p. S158, doi. 10.1016/j.pmrj.2017.08.023
- By:
- Publication type:
- Article
Poster 411 The Impact of OnabotulinumtoxinA on Severe Headache Days: PREEMPT 24‐Week Pooled Analysis.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2016, v. 8, n. 9, p. S296, doi. 10.1016/j.pmrj.2016.07.338
- By:
- Publication type:
- Article
Poster 281 The Adult Spasticity International Registry (ASPIRE Study): Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2016, v. 8, n. 9, p. S251, doi. 10.1016/j.pmrj.2016.07.454
- By:
- Publication type:
- Article
Poster 281 The Adult Spasticity International Registry (ASPIRE Study): Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2016, v. 8, p. S251, doi. 10.1016/j.pmrj.2016.07.454
- By:
- Publication type:
- Article
Poster 411 The Impact of OnabotulinumtoxinA on Severe Headache Days: PREEMPT 24-Week Pooled Analysis.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2016, v. 8, p. S296, doi. 10.1016/j.pmrj.2016.07.338
- By:
- Publication type:
- Article
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
- Published in:
- Pain & Therapy, 2021, v. 10, n. 2, p. 809, doi. 10.1007/s40122-021-00264-x
- By:
- Publication type:
- Article
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
- Published in:
- Pain & Therapy, 2020, v. 9, n. 2, p. 695, doi. 10.1007/s40122-020-00199-9
- By:
- Publication type:
- Article
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
- Published in:
- Pain & Therapy, 2020, v. 9, n. 2, p. 683, doi. 10.1007/s40122-020-00198-w
- By:
- Publication type:
- Article
Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 1, p. 69, doi. 10.1007/s40120-023-00556-8
- By:
- Publication type:
- Article
Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 5, p. 1533, doi. 10.1007/s40120-023-00529-x
- By:
- Publication type:
- Article
ADULT SPASTICITY INTERNATIONAL REGISTRY STUDY: METHODOLOGY AND BASELINE PATIENT, HEALTHCARE PROVIDER, AND CAREGIVER CHARACTERISTICS.
- Published in:
- Journal of Rehabilitation Medicine (Stiftelsen Rehabiliteringsinformation), 2017, v. 49, n. 8, p. 659, doi. 10.2340/16501977-2245
- By:
- Publication type:
- Article
Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01683-1
- By:
- Publication type:
- Article
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
- Published in:
- Journal of Headache & Pain, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s10194-023-01622-0
- By:
- Publication type:
- Article
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
- Published in:
- Cephalalgia, 2023, v. 43, n. 6, p. 1, doi. 10.1177/03331024231180611
- By:
- Publication type:
- Article
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons.
- Published in:
- Cephalalgia, 2021, v. 41, n. 1, p. 17, doi. 10.1177/0333102420970507
- By:
- Publication type:
- Article